Kita-gun
Kita-gun
Kita-gun, Kagawa-ken, Japan26 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-10-08 | NCT06976203 | |
| A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colon adenocarcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm, rectum adenocarcinoma | Recruiting | Phase 3 | 2026-10-07 | NCT06997497 | |
| A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 3 | 2026-10-06 | NCT07419295 | |
| Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL | primary central nervous system lymphoma | Active, not recruiting | Phase 1 | 2026-10-06 | NCT06541665 | |
| A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE) | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Enrolling by invitation | Phase 3 | 2026-10-05 | NCT05352919 | |
| A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration | Geographic Atrophy, age-related macular degeneration, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Phase 4 | 2026-09-30 | NCT06970665 | |
| REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis | Embolism, Embolism and Thrombosis, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thromboembolism, Venous Thrombosis, cardiovascular disorder, lung disorder, neoplasm, pulmonary embolism, respiratory system disorder, thrombotic disease, vascular disorder, venous thromboembolism | Recruiting | Phase 3 | 2026-09-29 | NCT07410117 | |
| A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue | Anorexia, Body Weight, Body Weight Changes, Cachexia, Digestive System Diseases, Digestive System Neoplasms, Fatigue, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Digestive, Thinness, Weight Loss, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-09-25 | NCT06989437 | |
| A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2026-09-22 | NCT07213674 | |
| Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 3 | 2026-09-16 | NCT06463587 | |
| Study of Out of Specification for Tisagenlecleucel | B-cell acute lymphoblastic leukemia, B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, Tumor Virus Infections, diffuse large B-cell lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Recruiting | Phase 3 | 2026-09-15 | NCT04094311 | |
| Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) | Skin and Connective Tissue Diseases, connective tissue disorder, muscle tissue disorder, musculoskeletal system disorder, polymyalgia rheumatica, rheumatic disorder | Active, not recruiting | Phase 3 | 2026-08-21 | NCT06331312 | |
| A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME | Diabetic Macular Edema (DME) | Active, not recruiting | Phase 2 / Phase 3 | 2026-08-20 | NCT06957080 | |
| Breakthrough Platform Trial for PCAS | Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, brain disorder, brain injury, cardiac arrest, cardiovascular disorder, central nervous system disorder, heart disorder, ischemia reperfusion injury, nervous system disorder, post-cardiac arrest syndrome, vascular disorder | Not yet recruiting | Not applicable | 2026-08-17 | NCT07769086 | |
| Hypothermia Versus Normothermia After Extracorporeal Cardiopulmonary Resuscitation for Out-of-hospital Cardiac Arrest | Out-of-Hospital Cardiac Arrest, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, brain disorder, brain injury, cardiac arrest, cardiovascular disorder, central nervous system disorder, heart disorder, ischemia reperfusion injury, nervous system disorder, post-cardiac arrest syndrome, vascular disorder | Recruiting | Not applicable | 2026-08-07 | NCT06776549 | |
| Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) | Head and Neck Neoplasms, Neoplasms by Site, autosomal dominant Parkinson disease 4, neoplasm | Active, not recruiting | Phase 3 | 2026-07-31 | NCT03765918 | |
| Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, urothelial carcinoma | Active, not recruiting | Phase 3 | 2026-07-22 | NCT05911295 | |
| A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2026-07-22 | NCT05253651 | |
| A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome | Primary Sjogrens Disease | Active, not recruiting | Phase 3 | 2026-04-16 | NCT06684847 | |
| Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer | Urothelial Cancer | Active, not recruiting | Phase 3 | 2026-03-06 | NCT03036098 | |
| A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK) | Aortic Arch Syndromes, Skin and Connective Tissue Diseases, Takayasu arteritis, aortic disorder, arteritis, cardiovascular disorder, skin disorder, skin vascular disease, vascular disorder, vasculitis | Active, not recruiting | Phase 3 | 2026-02-18 | NCT04161898 | |
| A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Active, not recruiting | Phase 3 | 2026-01-29 | NCT04961567 | |
| HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, amyloidosis, cardiomyopathy, cardiovascular disorder, familial amyloid neuropathy, heart disorder, hereditary amyloidosis, hereditary disease, inborn errors of metabolism, metabolic disease, proteostasis deficiencies | Active, not recruiting | Phase 3 | 2026-01-12 | NCT04153149 | |
| Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate adenocarcinoma, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2025-12-18 | NCT04446117 | |
| Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema | Diabetic Macular Edema (DME) | Active, not recruiting | Phase 2 | 2025-10-30 | NCT06116916 |